Recommendation of the President – Tecartus (brexucabtagene autoleucel)

Recommendation No. 61/2024 of June 17, 2024 of the President of the Agency for Health Technology Assessment and Tarification on the evaluation of the drug Tecartus (brexucabtagene autoleucel) within the framework of the drug program “Treatment of patients with acute lymphoblastic leukemia (ICD-10 C91.0)”.

Publication in Public Information Bulletin (BIP) >>